Nikhil I Khushalani

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 33

Top Topics

Monoclonal Antibody

Top Venues

Journal for immunotherapy of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Molecular cancer therapeutics

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B De Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari A Pilon-Thomas
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Molecular cancer therapeutics 23 (8) (2024)
Jeffrey S Weber, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A Fecher, Michael Millward, Nikhil I Khushalani, Paola Queirolo, Georgina V Long, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, James M G Larkin
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I Khushalani, Jason John Luke, Patrick A Ott, Jeffrey A Sosman, Vikram Aggarwal, Megan D Schollenberger, William H Sharfman, Kristin P Bibee, Jeffrey F Scott, Manisha J Loss, Hao Wang, Hanfei Qi, Elad Sharon, Howard Streicher, Helen X Chen, Robert N Woodward, Serena M Bagnasco, Janis M Taube, Suzanne L Topalian, Daniel C Brennan, Evan J Lipson
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Zachary Z Reinstein, Yue Zhang, Oscar E Ospina, Matt D Nichols, Victoria A Chu, Alvaro de Mingo Pulido, Karol Prieto, Jonathan V Nguyen, Rui Yin, Carlos Moran Segura, Ahmed Usman, Brittney R Sell, Spencer Ng, Janis V de la Iglesia, Sunandana Chandra, Jeffrey A Sosman, Raymond J Cho, Jeffrey B Cheng, Ellie N Ivanova, Sergei B Koralov, Robbert J C Slebos, Christine H Chung, Nikhil I Khushalani, Jane L Messina, Amod A Sarnaik, Jonathan S Zager, Vernon K Sondak, Charles J Vaske, Sungjune Kim, Andrew S Brohl, Xinlei Mi, Brian G Pierce, Xuefeng Wang, Brooke L Fridley, Kenneth Y Tsai, Jaehyuk Choi
Pre-existing skin-resident CD8 and gd T cell circuits mediate immune response in Merkel cell carcinoma and predict immunotherapy efficacy. Cancer discovery (2024)
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B De Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari A Pilon-Thomas
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Molecular cancer therapeutics 23 (8) (2024)
Tanya Ramadoss, Matthew Nichols, Christian Palacios, Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A Tarhini, Evan J Wuthrick, Vernon K Sondak, Nikhil I Khushalani, Kenneth Y Tsai, Andrew S Brohl
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma. Journal for immunotherapy of cancer 12 (9) (2024)
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I Khushalani, Jason John Luke, Patrick A Ott, Jeffrey A Sosman, Vikram Aggarwal, Megan D Schollenberger, William H Sharfman, Kristin P Bibee, Jeffrey F Scott, Manisha J Loss, Hao Wang, Hanfei Qi, Elad Sharon, Howard Streicher, Helen X Chen, Robert N Woodward, Serena M Bagnasco, Janis M Taube, Suzanne L Topalian, Daniel C Brennan, Evan J Lipson
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I Khushalani, Jason John Luke, Patrick A Ott, Jeffrey A Sosman, Vikram Aggarwal, Megan D Schollenberger, William H Sharfman, Kristin P Bibee, Jeffrey F Scott, Manisha J Loss, Hao Wang, Hanfei Qi, Elad Sharon, Howard Streicher, Helen X Chen, Robert N Woodward, Serena M Bagnasco, Janis M Taube, Suzanne L Topalian, Daniel C Brennan, Evan J Lipson
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B De Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari A Pilon-Thomas
First-in-human stage III/IV melanoma clinical trial of immune priming agent IFx-Hu2.0. Molecular cancer therapeutics (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B De Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari A Pilon-Thomas
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Molecular cancer therapeutics 23 (8) (2024)
Adi Diab, Helen J Gogas, Shahneen Sandhu, Georgina V Long, Paolo Antonio Ascierto, James M G Larkin, Mario Sznol, Fabio Franke, Tudor E Ciuleanu, Caio Pereira, Eva Muñoz Couselo, Fernanda Bronzon Damian, Michael Schenker, Aldo Perfetti, Celeste Lebbè, Gaëlle Quéreux, Friedegund Meier, Brendan D Curti, Carlos Rojas, Yull Arriaga, Haisu Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary A Tagliaferri, Nikhil I Khushalani
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
Michael B Atkins, Paolo Antonio Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet M Kluger, Ryan J Sullivan, Hussein A Tawbi
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. Journal for immunotherapy of cancer 11 (3) (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
Rahul Seth, Sanjiv S Agarwala, Hans Messersmith, Krishna C Alluri, Paolo Antonio Ascierto, Michael B Atkins, Kathryn Bollin, Matías Chacón, Nancy B Davis, Mark B Faries, Pauline Funchain, Jason S Gold, Samantha Guild, David E Gyorki, Varinder Kaur, Nikhil I Khushalani, Joanne M Jeter, Jennifer Leigh McQuade, Michael O Meyers, Anthony Provenzano, Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K Sondak, Gilliosa Spurrier, Umang Swami, Thach-Giao Truong, Katy K Tsai, Alexander C J van Akkooi, Jeffrey S Weber
Systemic Therapy for Melanoma: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Michael B Atkins, Paolo Antonio Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet M Kluger, Ryan J Sullivan, Hussein A Tawbi
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. Journal for immunotherapy of cancer 11 (3) (2023)
Joanne M Jeter, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang, Sigrun Hallmeyer, David H McDermott, Hussein A Tawbi, Min Che, Cho-Han Lee, Corey Ritchings, Trong Kim Le, Boas Park, Scott D Ramsey
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
James M G Larkin, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Mark Ross Middleton, Jose Lutzky, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew G Hill, Leslie A Fecher, Michael Millward, Paul D Nathan, Nikhil I Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo Antonio Ascierto, Jeffrey S Weber
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, Zeynep Eroglu, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Tomas Kirchhoff, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney, Ragini Kudchadkar, Joseph Markowitz, Andrew S Brohl, Anna Pavlick, Alison Richards, David M Woods, Jeffrey S Weber
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. Journal for immunotherapy of cancer 10 (11) (2022)
MacLean S Hall, John E Mullinax, Cheryl A Cox, Amy M Hall, Matthew S Beatty, Jamie Blauvelt, Patrick Innamarato, Luz E Nagle, Holly Branthoover, Doris Wiener, Benjamin I Schachner, Alberto J Martinez, Allison D Richards, Carolyn J Rich, Marjorie Colón Colón, Michael J Schell, Jamie K Teer, Nikhil I Khushalani, Jeffrey S Weber, James J Mule, Vernon K Sondak, Shari A Pilon-Thomas, Amod A Sarnaik
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Zeynep Eroglu, Kristy K Broman, John F Thompson, Amanda Nijhuis, Tina J Hieken, Lisa Kottschade, Jeffrey M Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Madalyn G Neuwirth, Avinash Sharma, Lesly Dossett, Tasha Hughes, David E Gyorki, Jennifer Downs, Giorgos Karakousis, Yun Song, Ann Lee, Russell S Berman, Alexander van Akkooi, Emma Stahlie, Dale Han, John Vetto, Georgia M Beasley, Norma E Farrow, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, Michael C Lowe, David W Ollila, Frances A Collichio, Roger Olofsson Bagge, Jan Mattsson, Hidde M Kroon, Harvey Chai, Jyri Teras, James Sun, Michael J Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi, Jonathan Zager, Nikhil I Khushalani
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection. Journal for immunotherapy of cancer 10 (8) (2022)
Vernon K Sondak, Rogerio I Neves, Evan J Wuthrick, Jane L Messina, Nikhil I Khushalani
Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma. Cancer 128 (21) (2022)
Daniel J Olson, Zeynep Eroglu, Bruce E Brockstein, Andrew S Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario Velasco, Jose Lutzky, Emily F Higgs, Riyue Bao, Timothy Clifford Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Vernon K Sondak, Thomas F Gajewski, Nikhil I Khushalani, Jason John Luke
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)
Amod A Sarnaik, Omid Hamid, Nikhil I Khushalani, Karl D Lewis, Theresa Medina, Harriet M Kluger, Sajeve S Thomas, Evidio Domingo-Musibay, Anna C Pavlick, Eric D Whitman, Salvador Martin-Algarra, Philippa Corrie, Brendan D Curti, Judit Oláh, Jose Lutzky, Jeffrey S Weber, James M G Larkin, Wen Shi, Toshimi Takamura, Madan Jagasia, Harry Qin, Xiao Wu, Cecile Chartier, Friedrich Graf Finckenstein, Maria Fardis, Joanne M Jeter, Jason A Chesney
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)
Nikhil I Khushalani, Adi Diab, Paolo Antonio Ascierto, James M G Larkin, Shahneen Sandhu, Mario Sznol, Henry B Koon, Anthony Jarkowski, Paul Statkevich, Paul Statkevich, William J Geese, Georgina V Long
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future oncology (London, England) 16 (28) (2020)